Company / Accounts Receivable
Esperion Therapeutics, Inc. Accounts Receivable History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Accounts Receivable
$140.2M
FY2025
5-year range
$22.9M / $140.2M
FY2021-FY2025
Trend
+74.9%
vs FY2024
Sector context
#42 of 113
Health Care
What the data says
At $140M, Esperion Therapeutics, Inc.'s accounts receivable ranks #42 of 113 in the Health Care sector. Accounts Receivable has increased for 5 consecutive years, from $12M in FY2020 to $140M in FY2025.
Based on SEC 10-K filings.
$140M in FY2025 with a 5-year CAGR of +62.5%.
Improved from $48M to $140M over the past 2 years.
Health Care sector context is included.
Accounts Receivable over time
Growth rates
- 3-Year CAGR
- +60.8%
- 5-Year CAGR
- +62.5%
- 10-Year CAGR
- -
Sector benchmark
#42 of 113 in Health CareTop 37% of 113This company $140.2M Sector average $1.1B
▼
-87.7% below sector average
Key checks
Key Insights
- Esperion Therapeutics, Inc.'s accounts receivable has grown for 5 consecutive years.
- 5-year CAGR of +62.5%, indicating consistent growth.
- In FY2025, accounts receivable increased 74.9% year-over-year.
- Ranks #42 out of 113 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score -1.60 (distress zone, below 1.8 threshold)
- Negative profit margin: -15.6%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Accounts ReceivableValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $140.2M | +74.9% |
| FY2024 | $80.1M | +65.3% |
| FY2023 | $48.5M | +43.8% |
| FY2022 | $33.7M | +47.1% |
| FY2021 | $22.9M | +85.1% |
| FY2020 | $12.4M | - |
| FY2019 | - | - |
| FY2018 | - | - |
| FY2017 | - | - |
| FY2016 | - | - |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026